7月9日，Ionis Pharmaceuticals盘前下跌14.75%，报74.68美元/股，成交额8.62万美元。
消息面上，Ionis与合作伙伴阿斯利康宣布，其药物Eplontersen针对转甲状腺素蛋白介导的淀粉样心肌病（ATTR-CM）的三期临床试验Cardio-Ttransform未能达到主要疗效终点。该终点为截至第140周与安慰剂相比的心血管死亡率及复发性心血管临床事件复合结局。公司表示，在当前以标准治疗（包括多数患者使用稳定剂）为基础的患者群体中，加用Eplontersen未提供具有统计学意义的获益。Ionis与阿斯利康计划继续分析完整数据，并于8月欧洲心脏病学会大会上公布结果。
Ionis是一家商业阶段生物技术公司，拥有七种已上市药物，管线覆盖神经病学、心脏代谢疾病等领域，此次ATTR-CM试验失败对其心脏代谢管线构成重大挫折。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.